LgR5 expression and cancer stem cell hypothesis: Clue to define the true origin of esophageal adenocarcinomas with and without Barrett's Esophagus?

Journal of Experimental and Clinical Cancer Research

Volumn 30, Issue 1, 2011, Pages

  Von Rahden, Burkhard H A ^a   Kircher, Stefan ^b   Lazariotou, Maria ^a   Reiber, Christoph ^a   Stuermer, Luisa ^a   Otto, Christoph ^a   Germer, Christoph T ^a   Grimm, Martin ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; KI 67 ANTIGEN; LEUCINE RICH REPEAT CONTAINING G PROTEIN COUPLED RECEPTOR; TRANSCRIPTION FACTOR CDX2; TUMOR MARKER; UNCLASSIFIED DRUG; G PROTEIN COUPLED RECEPTOR; LGR5 PROTEIN, HUMAN; MESSENGER RNA;

AGED; ANTIBODY LABELING; ARTICLE; BARRETT ESOPHAGUS; CANCER STEM CELL; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; UNIVARIATE ANALYSIS; ADENOCARCINOMA; CANCER STAGING; ESOPHAGUS TUMOR; GENETICS; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ADENOCARCINOMA; AGED; BARRETT ESOPHAGUS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; RECEPTORS, G-PROTEIN-COUPLED; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 79951850400     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-30-23     Document Type: Article

References (39)

1. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. H Pohl HG Welch, J Natl Cancer Inst 2005 97 2 142 146 10.1093/jnci/dji024 15657344 (Pubitemid 40277094)
2. Barrett's Esophagus and Barrett's Carcinoma. BHA von Rahden S HJ, Curr GERD Rep 2007 1 125 132 10.1007/s12171-007-0008-y
3. Clinical practice. Barrett's Esophagus. SJ Spechler, N Engl J Med 2002 346 11 836 842 10.1056/NEJMcp012118 11893796
4. Adenocarcinoma of the esophagus with and without Barrett mucosa. MS Sabel K Pastore H Toon JL Smith, Arch Surg 2000 135 7 831 835 discussion 836 10.1001/archsurg.135.7.831 10896378
5. Distinction between short-segment Barrett's esophageal and cardiac intestinal metaplasia. GS Liu J Gong P Cheng J Zhang Y Chang L Qiang, World J Gastroenterol 2005 11 40 6360 6365 16419166 (Pubitemid 43014005)
6. Is there a "Barrett's iceberg?". N Shaheen, Gastroenterology 2002 123 2 636 639 10.1053/gast.2002.35134 12145816
7. Antireflux surgery, barrett esophagus, and adenocarcinoma: there is still room for doubt. GG Jamieson, Ann Surg 2007 246 1 22 23 10.1097/SLA. 0b013e318070d3b7 17592285 (Pubitemid 47012201)
8. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. JE Visvader GJ Lindeman, Nat Rev Cancer 2008 8 10 755 768 10.1038/nrc2499 18784658
9. The clonal evolution of tumor cell populations. PC Nowell, Science 1976 194 4260 23 28 10.1126/science.959840 959840
10. Breast tumor heterogeneity: cancer stem cells or clonal evolution? LL Campbell K Polyak, Cell Cycle 2007 6 19 2332 2338 10.4161/cc.6.19.4914 17786053 (Pubitemid 350058682)
11. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. D Bonnet JE Dick, Nat Med 1997 3 7 730 737 10.1038/nm0797-730 9212098 (Pubitemid 27298715)
12. Wnt signalling in stem cells and cancer. T Reya H Clevers, Nature 2005 434 7035 843 850 10.1038/nature03319 15829953 (Pubitemid 40558990)
13. Acid, bile, and CDX: the ABCs of making Barrett's metaplasia. RF Souza K Krishnan SJ Spechler, Am J Physiol Gastrointest Liver Physiol 2008 295 2 211 218 10.1152/ajpgi.90250.2008 18556417
14. Age effects and temporal trends in adenocarcinoma of the esophagus and gastric cardia (United States). J Jeon EG Luebeck SH Moolgavkar, Cancer Causes Control 2006 17 7 971 981 10.1007/s10552-006-0037-3 16841264 (Pubitemid 44078288)
15. Crypt stem cells as the cells-of-origin of intestinal cancer. N Barker RA Ridgway JH van Es M van de Wetering H Begthel M van den Born E Danenberg AR Clarke OJ Sansom H Clevers, Nature 2009 457 7229 608 611 10.1038/nature07602 19092804
16. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. L Vermeulen M Todaro F de Sousa Mello MR Sprick K Kemper M Perez Alea DJ Richel G Stassi JP Medema, Proc Natl Acad Sci USA 2008 105 36 13427 13432 10.1073/pnas.0805706105 18765800
17. Identification of a novel putative gastrointestinal stem cell and adenoma stem cell marker, doublecortin and CaM kinase-like-1, following radiation injury and in adenomatous polyposis coli/multiple intestinal neoplasia mice. R May TE Riehl C Hunt SM Sureban S Anant CW Houchen, Stem Cells 2008 26 3 630 637 10.1634/stemcells.2007-0621 18055444
18. Selective blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a MicroRNA-dependent mechanism. SM Sureban R May S Ramalingam D Subramaniam G Natarajan S Anant CW Houchen, Gastroenterology 2009 137 2 649 659 659 e641-642 10.1053/j.gastro.2009.05.004 19445940
19. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. RW Phillips HF Frierson Jr CA Moskaluk, Am J Surg Pathol 2003 27 11 1442 1447 10.1097/00000478-200311000-00006 14576477 (Pubitemid 37315196)
20. Classification of adenocarcinoma of the oesophagogastric junction. JR Siewert HJ Stein, Br J Surg 1998 85 11 1457 1459 10.1046/j.1365-2168.1998.00940. x 9823902 (Pubitemid 28502569)
21. UICC. TNM Classification of Malignant Tumors. LH Sobin W Ch, 6 2002
22. Pathology and Genetics. Tumours of the Digestive System. SR Hamilton LA Aaltonen, Third 2000
23. The homeodomain protein CDX2 is an early marker of Barrett's oesophagus. LM Moons DA Bax EJ Kuipers H Van Dekken J Haringsma AH Van Vliet PD Siersema JG Kusters, J Clin Pathol 2004 57 10 1063 1068 10.1136/jcp.2003.015727 15452161 (Pubitemid 39331357)
24. Putative direct and indirect Wnt targets identified through consistent gene expression changes in APC-mutant intestinal adenomas from humans and mice. S Segditsas O Sieber M Deheragoda P East A Rowan R Jeffery E Nye S Clark B Spencer-Dene G Stamp, et al. Hum Mol Genet 2008 17 24 3864 3875 10.1093/hmg/ddn286 18782851 (Pubitemid 352762849)
25. Inactivating cholecystokinin-2 receptor inhibits progastrin-dependent colonic crypt fission, proliferation, and colorectal cancer in mice. G Jin V Ramanathan M Quante GH Baik X Yang SS Wang S Tu SA Gordon DM Pritchard A Varro, et al. J Clin Invest 2009 119 9 2691 2701 19652364
26. Nonparametric estimation from incomplete observations. EL Kaplan P Meier, J Am Stat Assoc 1958 75 457 487 10.2307/2281868
27. Regression models and life tables. DR Cox, J R Stat Soc 1972 34 1987 2001
28. Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with beta-catenin mutations. Y Yamamoto M Sakamoto G Fujii H Tsuiji K Kenetaka M Asaka S Hirohashi, Hepatology 2003 37 3 528 533 10.1053/jhep.2003.50029 12601349 (Pubitemid 36258773)
29. G-protein-coupled receptor GPR49 is up-regulated in basal cell carcinoma and promotes cell proliferation and tumor formation. K Tanese M Fukuma T Yamada T Mori T Yoshikawa W Watanabe A Ishiko M Amagai T Nishikawa M Sakamoto, Am J Pathol 2008 173 3 835 843 10.2353/ajpath.2008.071091 18688030
30. In Pursuit of Leucine-Rich Repeat-Containing G Protein-Coupled Receptor-5 Regulation and Function in the Uterus. X Sun L Jackson SK Dey T Daikoku, Endocrinology 2009 150 11 5065 5073 10.1210/en.2009-0690 19797400
31. Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors. T McClanahan S Koseoglu K Smith J Grein E Gustafson S Black P Kirschmeier AA Samatar, Cancer Biol Ther 2006 5 4 419 426 10.4161/cbt.5.4.2521 16575208
32. Gastrointestinal stem cells in development and cancer. S Brabletz O Schmalhofer T Brabletz, J Pathol 2009 217 2 307 317 10.1002/path.2475 19031475
33. Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett's esophagus and esophageal adenocarcinoma. L Becker Q Huang H Mashimo, Dis Esophagus 2010 23 2 168 174 10.1111/j.1442-2050.2009.00979.x 19549212
34. An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes. L Melchor J Benitez, Carcinogenesis 2008 29 8 1475 1482 10.1093/carcin/bgn157 18596026
35. Cancer stem cells: an old idea - a paradigm shift. MS Wicha S Liu G Dontu, Cancer Res 2006 66 4 1883 1890 discussion 1895-1886 10.1158/0008-5472. CAN-05-3153 16488983
36. Immunostaining of Lgr5, an intestinal stem cell marker, in normal and premalignant human gastrointestinal tissue. L Becker Q Huang H Mashimo, ScientificWorldJournal 2008 8 1168 1176 10.1100/tsw.2008.148 19030762
37. Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. AJ Cameron CT Lomboy M Pera HA Carpenter, Gastroenterology 1995 109 5 1541 1546 10.1016/0016-5085(95)90642-8 7557137
38. Preoperative chemotherapy unmasks underlying Barrett's mucosa in patients with adenocarcinoma of the distal esophagus. J Theisen HJ Stein HJ Dittler M Feith C Moebius WK Kauer M Werner JR Siewert, Surg Endosc 2002 16 4 671 673 10.1007/s00464-001-8307-3 11972212 (Pubitemid 34263435)
39. Multifocal lung cancers - clonality vs field cancerization and does it matter? AF Gazdar JD Minna, J Natl Cancer Inst 2009 101 8 541 543 10.1093/jnci/djp059 19351914